A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen

NCT00615056 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

171

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

DRUG: Bevacizumab (avastin)
DRUG: FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])
DRUG: AG-013736 (axitinib)
DRUG: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
DRUG: AG-013736 (axitinib)
DRUG: FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])
DRUG: Bevacizumab (avastin)
DRUG: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])

Sponsor

Pfizer